Feeds:
Posts
Comments

Search Results for 'Pharmacotherapy of Cardiovascular Disease'

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN   Article NameLive Link ViewsAll Time Categories of Research   #1 Is the Warburg Effect the Cause or the Effect […]

Read Full Post »

Zachary Day, Research Assistant 2, Exploration in Marketing Communications https://pharmaceuticalintelligence.com/contributors-biographies/research-assistants/zachary-day-research-assistant-2-exploration-in-marketing-communications/ Assignment #4 Article Information Article NameLive Link Views All Time Categories of Research Interaction of enzymes and hormones 5,179 Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Metabolomics, Population Health Management, Genetics & Pharmaceutical, Population Health Management, Nutrition and […]

Read Full Post »

Transthyretin amyloid cardiomyopathy (ATTR-CM): U.S. FDA APPROVES VYNDAQEL® AND VYNDAMAX™ for this Rare and Fatal Disease Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 6/30/2021 CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis June 26, 2021 DOI: 10.1056/NEJMoa2107454 Abstract Background Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening disease characterized by progressive accumulation of misfolded […]

Read Full Post »

Cardiovascular (CV) Disease and Diabetes: New ACC Guidelines for use of two major new classes of diabetes drugs — sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) for reduction of adverse outcomes Reporter: Aviva Lev-Ari, PhD, RN   “The main aim for this report is to educate cardiologists, who might not otherwise think […]

Read Full Post »

Risks from Dual Antiplatelet Therapy (DAPT) may be reduced by Genotyping Guidance of Cardiac Patients Reporter: Aviva Lev-Ari, PhD, RN   Genotyping Cardiac Patients May Reduce Risks From DAPT -STEMI patient study reaches noninferiority mark for adverse cardiac events by Vicki Brower, CME Writer, MedPage Today September 7, 2019 In the investigational arm, all 1,242 patients were tested […]

Read Full Post »

Injectable inclisiran (siRNA) as 3rd anti-PCSK9 behind mAbs Repatha and Praluent Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 4/27/2021 Combining AstraZeneca’s ‘good’ cholesterol booster with PCSK9 inhibition shows promise in heart disease by Angus Liu | Apr 21, 2021 3:00pm The drug, dubbed MEDI5884, is designed to neutralize a circulating enzyme called endothelial lipase. The protein regulates […]

Read Full Post »

@Cleveland Clinic – Serial measurements of high-sensitivity C-reactive protein (hsCRP) post acute coronary syndrome (ACS) may help identify patients at higher risk for morbidity and mortality   Reporter: Aviva Lev-Ari, PhD, RN   Original Investigation March 6, 2019 Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary […]

Read Full Post »

The Promise of Low-Dose Aspirin on Longevity in the Geriatric Population: No Effect on Outcomes in the US and Australia Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 10/17/2018 https://www.nejm.org/doi/full/10.1056/NEJMoa1800722 Effect of Aspirin on Disability-free Survival in the Elderly ORIGINAL ARTICLE Effect of Aspirin on Disability-free Survival in the Healthy Elderly J.J. McNeil and Others      […]

Read Full Post »

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN   Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]

Read Full Post »

A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab), a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway Reporter: Aviva Lev-Ari, PhD, RN   Speaking at an ESC press briefing, Ridker said, “This is what personalized predictive medicine is all about.” Once a patient has […]

Read Full Post »

Next »

%d bloggers like this: